Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in virus-associated solid tumors
NCT02488759Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2015
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of nivolumab in Merkel cell carcinoma (MCC), gastric cancer (GC), nasopharyngeal carcinoma (NPC), Cervical Cancer (CC), vaginal cancer, sponsored by Bristol Myers Squibb. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)gastric cancer (GC)nasopharyngeal carcinoma (NPC)Cervical Cancer (CC)vaginal cancer
Beyond the preview
Go deeper on NCT02488759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488759.